These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2659737)

  • 1. Interferon-alpha and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. AUSTIMS Research Group.
    J Neurol Neurosurg Psychiatry; 1989 May; 52(5):566-74. PubMed ID: 2659737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfer factor in treatment of multiple sclerosis.
    Basten A; McLeod JG; Pollard JD; Walsh JC; Stewart GJ; Garrick R; Frith JA; Van Der Brink CM
    Lancet; 1980 Nov; 2(8201):931-4. PubMed ID: 6107585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.
    Camenga DL; Johnson KP; Alter M; Engelhardt CD; Fishman PS; Greenstein JI; Haley AS; Hirsch RL; Kleiner JE; Kofie VY
    Arch Neurol; 1986 Dec; 43(12):1239-46. PubMed ID: 3535752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfer factor therapy in multiple sclerosis: a three-year prospective double-blind clinical trial.
    Van Haver H; Lissoir F; Droissart C; Ketelaer P; Van Hees J; Theys P; Vervliet G; Claeys H; Gautama K; Vermylen C
    Neurology; 1986 Oct; 36(10):1399-402. PubMed ID: 3093918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.
    Milanese C; Salmaggi A; La Mantia L; Campi A; Eoli M; Savoiardo M; Bianchi G; Nespolo A
    J Neurol Neurosurg Psychiatry; 1990 Jul; 53(7):554-7. PubMed ID: 1697334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment.
    Warren KG; Catz I; Ferenczi LZ; Krantz MJ
    Eur J Neurol; 2006 Aug; 13(8):887-95. PubMed ID: 16879301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The placebo effect during a double blind trial of recombinant alpha 2 interferon in multiple sclerosis patients: immunological and clinical findings.
    Hirsch RL; Johnson KP; Camenga DL
    Int J Neurosci; 1988 Apr; 39(3-4):189-96. PubMed ID: 3045033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind trial of transfer factor vs placebo in multiple sclerosis patients.
    Collins RC; Espinoza LR; Plank CR; Ebers GC; Rosenberg RA; Zabriskie JB
    Clin Exp Immunol; 1978 Jul; 33(1):1-11. PubMed ID: 361313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfer factor as a therapy for multiple sclerosis: a follow-up study.
    Frith JA; McLeod JG; Basten A; Pollard JD; Hammond SR; Williams DB; Crossie PA
    Clin Exp Neurol; 1986; 22():149-54. PubMed ID: 3555898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation.
    Kastrukoff LF; Oger JJ; Hashimoto SA; Sacks SL; Li DK; Palmer MR; Koopmans RA; Petkau AJ; Berkowitz J; Paty DW
    Neurology; 1990 Mar; 40(3 Pt 1):479-86. PubMed ID: 2179764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical and immunological study of the effects of transfer factor on multiple sclerosis patients.
    Lamoureux G; Cosgrove J; Duquette P; Lapierre Y; Jolicoeur R; Vanderland F
    Clin Exp Immunol; 1981 Mar; 43(3):557-64. PubMed ID: 7026094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon.
    Panitch HS; Francis GS; Hooper CJ; Merigan TC; Johnson KP
    Ann Neurol; 1985 Oct; 18(4):434-8. PubMed ID: 2416265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term transfer-factor treatment for multiple sclerosis.
    Fog T; Pedersen L; Raun NE; Kam-Hansen S; Mellerup E; Platz P; Ryder LP; Jakobsen BK; Grob P
    Lancet; 1978 Apr; 1(8069):851-3. PubMed ID: 76798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic interferon therapy of multiple sclerosis: the pros.
    Knobler RL
    Neurology; 1988 Jul; 38(7 Suppl 2):58-61. PubMed ID: 3133575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic alpha-interferon therapy of multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CK; Kamin-Lewis RM; Johnson KP
    Neurology; 1984 Oct; 34(10):1273-9. PubMed ID: 6384817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, double-blind, placebo-controlled trial of transfer factor as adjuvant therapy for malignant melanoma.
    Miller LL; Spitler LE; Allen RE; Minor DR
    Cancer; 1988 Apr; 61(8):1543-9. PubMed ID: 3280114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.